439 related articles for article (PubMed ID: 11570875)
1. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
Kvassman JO; Verhamme I; Shore JD
Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
[TBL] [Abstract][Full Text] [Related]
3. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
4. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F.
Komissarov AA; Zhou A; Declerck PJ
J Biol Chem; 2007 Sep; 282(36):26306-15. PubMed ID: 17613529
[TBL] [Abstract][Full Text] [Related]
5. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes.
Olson ST; Bock PE; Kvassman J; Shore JD; Lawrence DA; Ginsburg D; Björk I
J Biol Chem; 1995 Dec; 270(50):30007-17. PubMed ID: 8530403
[TBL] [Abstract][Full Text] [Related]
6. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition.
Ibarra CA; Blouse GE; Christian TD; Shore JD
J Biol Chem; 2004 Jan; 279(5):3643-50. PubMed ID: 14594804
[TBL] [Abstract][Full Text] [Related]
7. A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition.
Blouse GE; Perron MJ; Thompson JH; Day DE; Link CA; Shore JD
Biochemistry; 2002 Oct; 41(40):11997-2009. PubMed ID: 12356300
[TBL] [Abstract][Full Text] [Related]
8. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
[TBL] [Abstract][Full Text] [Related]
9. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
Egelund R; Petersen TE; Andreasen PA
Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
[TBL] [Abstract][Full Text] [Related]
10. Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator.
Komissarov AA; Declerck PJ; Shore JD
J Biol Chem; 2004 May; 279(22):23007-13. PubMed ID: 15033993
[TBL] [Abstract][Full Text] [Related]
11. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
[TBL] [Abstract][Full Text] [Related]
12. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
[TBL] [Abstract][Full Text] [Related]
13. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.
Shore JD; Day DE; Francis-Chmura AM; Verhamme I; Kvassman J; Lawrence DA; Ginsburg D
J Biol Chem; 1995 Mar; 270(10):5395-8. PubMed ID: 7890653
[TBL] [Abstract][Full Text] [Related]
14. Distortion of the catalytic domain of tissue-type plasminogen activator by plasminogen activator inhibitor-1 coincides with the formation of stable serpin-proteinase complexes.
Perron MJ; Blouse GE; Shore JD
J Biol Chem; 2003 Nov; 278(48):48197-203. PubMed ID: 14500731
[TBL] [Abstract][Full Text] [Related]
15. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.
Fa M; Karolin J; Aleshkov S; Strandberg L; Johansson LB; Ny T
Biochemistry; 1995 Oct; 34(42):13833-40. PubMed ID: 7577977
[TBL] [Abstract][Full Text] [Related]
16. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
17. Formation of a noncovalent serpin-proteinase complex involves no conformational change in the serpin. Use of 1H-15N HSQC NMR as a sensitive nonperturbing monitor of conformation.
Peterson FC; Gordon NC; Gettins PG
Biochemistry; 2000 Oct; 39(39):11884-92. PubMed ID: 11009600
[TBL] [Abstract][Full Text] [Related]
18. Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions.
Al-Ayyoubi M; Schwartz BS; Gettins PG
J Biol Chem; 2007 Jul; 282(27):19502-9. PubMed ID: 17510061
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1' determined by donor-donor fluorescence energy transfer.
Aleshkov SB; Fa M; Karolin J; Strandberg L; Johansson LB; Wilczynska M; Ny T
J Biol Chem; 1996 Aug; 271(35):21231-8. PubMed ID: 8702896
[TBL] [Abstract][Full Text] [Related]
20. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.
Aertgeerts K; De Ranter CJ; Booth NA; Declerck PJ
J Struct Biol; 1997 Apr; 118(3):236-42. PubMed ID: 9169233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
